Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuT cell receptor gene therapy for cancerAdoptive cell transfer: a clinical path to effective cancer immunotherapyCancer regression in patients after transfer of genetically engineered lymphocytesGenetic engineering with T cell receptorsGenetically modified T cells in cancer therapy: opportunities and challengesImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesStructural Basis of the CD8 /MHC Class I Interaction: Focused Recognition Orients CD8 to a T Cell Proximal PositionT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesT-cell receptor gene therapy--ready to go viral?Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesHow (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaMHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma modelDirect tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Strategies to genetically engineer T cells for cancer immunotherapy.HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer.Mixed T cell receptor dimers harbor potentially harmful neoreactivity.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunitySpecific increase in potency via structure-based design of a TCR.Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer.Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.Probing the effector and suppressive functions of human T cell subsets using antigen-specific engineered T cell receptorsT cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Engineering improved T cell receptors using an alanine-scan guided T cell display selection systemGenetically engineered T cells for the treatment of cancer.A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor controlDevelopment of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.Specific roles of each TCR hemichain in generating functional chain-centric TCR.Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.Treating cancer with genetically engineered T cells.
P2860
Q21131200-BB4EE2C2-28F5-40B3-8927-680E746CC01DQ24634774-75BC93D4-657F-48BD-8410-CAE86617F487Q24644774-154D4843-CC30-49F7-90AC-01F0BAF5E2C4Q24654976-AAFEB1F6-F0A7-4B71-8CCE-241F06F487EEQ26995677-DFF86A65-6C04-474F-9A76-8317EFEB8BC3Q27026627-40B46A44-9A5D-4BC8-A6DA-5481C8920D82Q27027243-DB39B5EF-64A5-452C-B5C9-6A3E42895FBBQ27656650-3A007B18-7FD0-47FC-9DFE-2BABEFB270B5Q28074619-CED26075-C8C9-49DB-B420-FEB0CCDB8CFEQ28081611-99AD2111-AB48-4324-83CD-CCBD3A5EEB00Q28085769-D1F1E40F-C839-42B4-8A17-BD3BEEC51C67Q28727481-B74AB3ED-190B-46FF-A517-F6B2B8ECB635Q28749871-03693F5E-6759-4381-AB30-8B5E1254C985Q30303138-B8C2B149-0920-481C-9173-EDE7DAACAD31Q30437670-2A8E6693-C1EF-41AE-AC6C-7BEF8E011C05Q30667174-F5844EF3-CD56-4A83-885E-9A30E3651887Q33530527-9FDDB9F0-6CDF-4067-8244-4F9D1DC04EDDQ33655849-1DB6A041-AE48-4929-A57E-8012099E54CEQ33735871-23341D14-7BD7-4C54-9E96-2FA1C8C3A464Q33934631-C794BF55-25D5-4A3F-AFE5-F4DB80F5F071Q34042430-C74E5A55-4046-4E27-8BAB-1FC5BEBC4F71Q34063596-8559BD40-75C7-4735-BE1C-A2C4E427439AQ34084756-1A3901F9-9B75-46A7-882B-FDCE50DA0052Q34245409-45122AC7-42F2-4166-9194-8AAAFED8CFAEQ34360174-41167FFE-AA6E-4BC3-BD70-992F49B5F40EQ34383054-B1B445CF-717C-4884-B5D3-7DCFCD727087Q34506910-2FBB78AA-86FD-4742-A955-BD6742C26AF6Q34519488-2002071B-9305-4FC1-B58A-4296C8C04961Q34598553-AE1E6E11-4475-4129-B77A-16CB89668D1BQ34621730-CE41C37F-33B7-4650-BD60-26460783CA69Q34624124-B68D7CEF-E4B5-45BF-AF0B-D45BEF1FFC1DQ34645898-5B76BB14-EC6E-492D-BEC7-88CAD9774AC7Q34670378-2AF4BF0C-A9A9-4682-85C7-6C72D8BE253CQ34678708-469AEA5F-FD98-4AF0-9459-9D30374924D1Q35102451-17749050-EE10-43B1-B4B7-CE5B27283956Q35135031-DBE96003-678F-4EDE-A635-B00D8EEC2DACQ35205495-245F6CE0-8535-4D06-AF36-02BA8AD0A3E6Q35208290-87A67578-A37B-4FF9-86E7-3A2FE5963068Q35221732-39581B3A-7664-4351-B6F0-479628B8DC08Q35353365-646C08F1-099A-41FF-9E31-63AE2659AF94
P2860
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@ast
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@en
type
label
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@ast
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@en
prefLabel
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@ast
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@en
P2093
P2860
P1433
P1476
Enhanced antitumor activity of ...... pairing and TCR/CD3 stability.
@en
P2093
Cyrille J Cohen
Richard A Morgan
Steven A Rosenberg
Yangbing Zhao
Zhili Zheng
P2860
P304
P356
10.1158/0008-5472.CAN-06-1450
P407
P577
2006-09-01T00:00:00Z